한글목차

축성 척추관절염(axSpA)의 동향과 예측

세계 축성 척추관절염(axSpA) 시장은 비스테로이드성 항염증제(NSAIDs), 글루코코르티코이드, 항류마티스제제 시장에서 기회와 잠재력이 있는 시장입니다. 세계 축성 척추관절염(axSpA) 시장은 2024년부터 2030년까지 6.5%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년까지 약 96억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 고령화 인구의 급격한 증가, 척추 관절염의 유병률 증가, 효과적인 치료법을 개발하기 위한 제약 회사의 연구 개발 활동 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 강직성 척추염(AS)이 예측 기간 동안 높은 성장세를 보일 것으로 예상됩니다.
• 약물 유형별로는 비스테로이드성 항염증제(NSAIDs)가 수술 후 통증을 완화하고 의사의 처방이 많기 때문에 가장 높은 성장이 예상됩니다.
• 지역별로는 북미가 인지도 향상과 유병률 증가로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

축성 척추관절염(axSpA) 시장의 전략적 성장 기회

체간척추관절염(axSpA) 시장은 다양한 응용 분야에서 몇 가지 전략적 성장 기회를 제공합니다. 이러한 기회를 식별하고 활용하면 시장 확대와 혁신을 촉진할 수 있습니다.

• 소아 치료: 소아 겨드랑이 척추염을 치료하기 위한 연령별 제제 개발은 고유한 요구를 가진 특수 환자 그룹에 대응할 수 있는 기회를 제공하고 궁극적으로 시장을 확대할 수 있습니다.
• 조기 진단 및 조기 개입: 첨단 진단 도구를 통해 axSpA를 조기에 발견할 수 있어 환자의 예후를 개선하고 장기적인 의료 비용을 크게 절감할 수 있습니다.
• 농촌 의료 접근성: 원격 의료 및 이동식 의료기기를 농촌 및 의료 서비스가 부족한 지역에 활용함으로써 axSpA 치료에 대한 접근성을 개선하고, 도시와 농촌의 의료 시스템 격차를 해소하고 의료 격차를 줄일 수 있습니다.
• 노인 의료: axSPA와 같은 근골격계 질환에 걸리기 쉬운 노인 인구 증가는 표적 치료에 대한 수요를 증가시켜 노인 의료 분야에서 새로운 기회를 제공할 것입니다.
• 코로나19 이후 치료제: 코로나19로 인한 장기적인 근골격계 합병증에 대처하는 것은 axSpA 치료의 새로운 시장 부문을 제시하며, 환자 결과를 개선하는 동시에 성장 잠재력을 제공합니다.

이러한 성장 기회는 axSpA 시장의 기술 혁신과 시장 확대의 원동력이 되고 있습니다. 기술 발전을 통해 환자의 다양한 요구를 충족시킴으로써 시장은 지속적인 성장을 이룰 수 있습니다.

축성 척추관절염(axSpA) 시장 성장 촉진요인 및 과제

체간척추관절염(axSpA) 시장은 다양한 기술적, 경제적, 규제적 요인의 영향을 받습니다. 이러한 시장 성장 촉진요인과 과제를 이해하는 것은 시장의 역동적인 특성을 잘 활용하고 경제적 성공을 거두는 데 있어 매우 중요합니다.

axSpA 시장의 주요 촉진요인은 다음과 같습니다.

1. 기술 발전: 첨단 진단 도구 및 디지털 헬스 기술 등 기술 혁신으로 axSpA 치료 관리가 용이해져 시장 성장에 기여합니다.

2.2.2.axSpA 유병률 증가: axSpA 환자 수가 증가함에 따라 효과적인 치료 옵션이 필요하며, 이는 시장 성장을 가속하고 이 분야의 기술 혁신을 촉진하고 있습니다.

3. 인구 고령화: 세계 인구의 고령화에 따라 axSpA와 같은 근골격계 질환의 유병률이 증가하면서 치료에 대한 수요가 증가하여 시장 성장에 기여하고 있습니다.

4. 정부의 이니셔티브: 특히 신흥국에서는 의료 인프라를 개선하고 axSpA 치료에 대한 접근성을 높이기 위한 정부의 이니셔티브이 수요를 촉진하고 있습니다.

5.R&D 투자 증가: 제약회사와 정부는 R&D에 대한 투자를 확대하고 있으며, 이는 axSpA 시장에서 새로운 치료법 및 혁신 개발로 이어지고 있습니다.

axSpA 시장이 직면한 과제는 다음과 같습니다.

1. 높은 치료비: 첨단 치료, 특히 생물학적 제제의 높은 치료비는 환자의 치료 접근성을 제한하고 시장 성장을 저해할 수 있습니다.

2. 규제 장애물: 엄격한 규제 요건과 긴 승인 절차로 인해 새로운 치료법의 도입이 지연되고 시장 성장에 영향을 미칠 수 있습니다.

3. 시장 경쟁: 제네릭 의약품 및 대체요법과의 치열한 경쟁은 가격과 시장 점유율을 압박하고, 주요 기업들은 그 지위를 유지하기 위해 지속적인 기술 혁신을 해야만 합니다.

이러한 시장 성장 촉진요인과 과제가 시장 역학을 형성하고 있습니다. 이러한 경쟁 환경에서 성공하고자 하는 기업은 이러한 요인을 이해해야 시장 상황을 효과적으로 헤쳐나갈 수 있습니다.

목차

제1장 주요 요약

제2장 세계의 축성 척추관절염(axSpA) 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 축성 척추관절염(axSpA) 시장 동향(2018-2023년)과 예측(2024-2030년)
• 축성 척추관절염(axSpA) 세계 시장, 유형별
  • 강직성 척추염(AS)
  • 비방사선학적 축성 척추관절염(nr-axSpA)
• 축성 척추관절염(axSpA) 세계 시장, 약제 클래스별
  • 비스테로이드성 항염증제(NSAID)
  • 글루코코르티코이드
  • 항류머티즘제
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 축성 척추관절염(axSpA) 세계 시장
• 북미의 축성 척추관절염(axSpA) 시장
• 유럽의 축성 척추관절염(axSpA) 시장
• 아시아태평양의 축성 척추관절염(axSpA) 시장
• 기타 지역의 축성 척추관절염(axSpA) 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 세계의 축성 척추관절염(axSpA) 시장 성장 기회
  • 약제 클래스별 세계의 축성 척추관절염(axSpA) 시장 성장 기회
  • 지역별 세계의 축성 척추관절염(axSpA) 시장 성장 기회
• 세계의 축성 척추관절염(axSpA) 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 축성 척추관절염(axSpA) 시장 능력 확대
  • 세계 축성 척추관절염(axSpA) 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Janssen Biotech
• AbbVie
• UCB
• Amgen
• Novartis Pharmaceuticals Corporation

영문목차

Axial Spondyloarthritis (AXSPA) Trends and Forecast

The future of the global axial spondyloarthritis (AXSPA) market looks promising with opportunities in the non-steroidal anti-inflammatory drug (NSAID), glucocorticoid, and anti-rheumatic drug markets. The global axial spondyloarthritis (AXSPA) market is expected to reach an estimated $9.6 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are a surge in the aging population, the rising prevalence of spondyloarthritis, and growing research and development activities by pharmaceutical companies to develop effective treatments.

• Lucintel forecasts that, within the type category, ankylosing spondylitis (AS) is expected to witness higher growth over the forecast period.
• Within the drug class category, non-steroidal anti-inflammatory drug (NSAIDs) is expected to witness the highest growth due to their help to relieve pain after surgery and are mostly prescribed by doctors.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to an increase in awareness and rising prevalence of disease.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Axial Spondyloarthritis (AXSPA) Market

Emerging trends in the axial spondyloarthritis (AxSpA) market are reshaping its future applications and dynamics:

• Personalized Medicine: The adoption of personalized medicine in AxSpA is gaining popularity, guided by genomic testing, which leads to targeted therapies. This allows treatments to be tailored to individual profiles, reducing side effects and improving overall outcomes.
• Biosimilars: The introduction and acceptance of biosimilars are increasing due to their lower cost compared to biologics. This makes treatments more accessible to a larger patient population, thereby contributing to market growth.
• Digital Health Technologies: Digital health technologies, such as telemedicine and mobile health apps, are increasingly used in AxSpA management. These tools improve monitoring, enhance adherence to treatment plans, and provide real-time data to aid medical decision-making.
• Combination Therapies: Combination therapies, which include several active components, are becoming more common in treating AxSpA. These formulations simplify treatment regimens, enhance patient compliance, and target multiple disease pathways, leading to improved therapeutic outcomes.
• Patient-Centric Care: There is a growing shift toward holistic treatment approaches that focus on improving the overall quality of life for patients. Emphasis is being placed on patient education, lifestyle modifications, and comprehensive management plans that address both physical and mental health aspects.

These emerging trends are reshaping the AxSpA market, driving innovation and improving patient care. These trends will have a significant impact on market growth and direction as they continue to evolve.

Recent Developments in the Axial Spondyloarthritis (AXSPA) Market

Recent developments in the axial spondyloarthritis market include a range of innovations and advancements:

• New Drug Approvals: The approval of new biologics and biosimilars for AxSpA is expanding the therapeutic options available to patients, leading to better treatment outcomes and improved quality of life.
• Technological Innovations: Advancements such as improved diagnostic tools and digital health technologies are enhancing the detection and management of AxSpA, improving patient adherence to treatment regimens.
• Strategic Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of novel therapeutics, leading to improved clinical outcomes through combined expertise and resources.
• Regulatory Advancements: Regulatory advancements, including faster approval processes and incentives for orphan drug development, are encouraging innovation in the AxSpA market, enabling quicker access to cutting-edge treatments.
• Increased R&D Investment: Rising research and development funding from both the private sector and governments is facilitating the discovery of new therapeutic targets and the development of advanced treatments for AxSpA.

These developments are significantly influencing the AxSpA market by fostering innovation, enhancing patient outcomes, and expanding treatment options. They will play a crucial role in the market's continued expansion.

Strategic Growth Opportunities for Axial Spondyloarthritis (AXSPA) Market

The axial spondyloarthritis (AxSpA) market presents several strategic growth opportunities across various applications. Identifying and capitalizing on these opportunities can drive market expansion and innovation:

• Pediatric Treatment: Developing age-specific formulations for treating AxSpA in children offers an opportunity to address a special patient group with unique needs, ultimately expanding the market.
• Early Diagnosis and Intervention: Advanced diagnostic tools enable earlier detection of AxSpA, leading to better patient outcomes and significant long-term healthcare cost savings.
• Rural Healthcare Access: The use of telemedicine and mobile healthcare units in rural and underserved areas can improve access to AxSpA treatments, bridging the gap between urban and rural healthcare systems and reducing health disparities.
• Geriatric Care: The increasing elderly population, who are more likely to develop musculoskeletal disorders like AxSpA, creates a growing demand for targeted treatments, offering new opportunities in geriatric care.
• Post-COVID-19 Therapeutics: Addressing long-term musculoskeletal complications resulting from COVID-19 presents a new market segment for AxSpA treatments, offering the potential for growth while also improving patient outcomes.

These growth opportunities are driving innovation and market expansion in the AxSpA market. By meeting various patient needs through technological advancements, the market can achieve sustainable growth.

Axial Spondyloarthritis (AXSPA) Market Driver and Challenges

The axial spondyloarthritis (AxSpA) market is influenced by various technological, economic, and regulatory factors. Understanding these drivers and challenges is crucial for navigating the dynamic nature of the market and achieving financial success.

The key drivers of the AxSpA market include:

1. Technological Advancements: Technological innovations, such as advanced diagnostic tools and digital health technologies, improve the ease of managing AxSpA treatments, contributing to market growth.

2. Increasing Prevalence of AxSpA: The rising number of individuals affected by AxSpA necessitates effective treatment options, driving market growth and spurring further innovation in the field.

3. Aging Population: As the global population ages, the incidence of musculoskeletal disorders like AxSpA increases, leading to higher demand for treatments and contributing to market growth.

4. Government Initiatives: Particularly in emerging economies, government efforts to improve healthcare infrastructure and increase access to AxSpA treatments are pushing up demand.

5. Increased R&D Investment: Pharmaceutical companies and governments are investing more heavily in R&D, leading to the development of new treatments and innovations in the AxSpA market.

Challenges facing the AxSpA market include:

1. High Treatment Costs: The high cost of advanced therapies, particularly biologics, can limit patient access to treatment and hinder market growth.

2. Regulatory Hurdles: Stringent regulatory requirements and lengthy approval processes can slow the introduction of new treatments, impacting market growth.

3. Market Competition: Intense competition from generic drugs and alternative therapies can put pressure on prices and market share, compelling key players to continually innovate to maintain their position.

These drivers and challenges shape the market's dynamics. Companies seeking success in this competitive industry must understand these factors to effectively navigate the market landscape.

List of Axial Spondyloarthritis (AXSPA) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies axial spondyloarthritis (AXSPA) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the axial spondyloarthritis (AXSPA) companies profiled in this report include-

• Janssen Biotech
• AbbVie
• UCB
• Amgen
• Novartis Pharmaceuticals Corporation

Axial Spondyloarthritis (AXSPA) by Segment

The study includes a forecast for the global axial spondyloarthritis (AXSPA) by type, drug class, and region.

Axial Spondyloarthritis (AXSPA) Market by Type [Analysis by Value from 2018 to 2030]:

• Ankylosing Spondylitis (AS)
• Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (AXSPA) Market by Drug Class [Analysis by Value from 2018 to 2030]:

• Non-Steroidal Anti-Inflammatory Drugs (NSAID)
• Glucocorticoids
• Anti-Rheumatic Drugs
• Others

Axial Spondyloarthritis (AXSPA) Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Axial Spondyloarthritis (AXSPA) Market

Major players in the AxSpA market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments from key regions: the USA, China, India, Japan, and Germany.

• United States: The FDA has recently approved new biologics and biosimilars for AxSpA. There is also a growing focus on patient-centric approaches, incorporating advanced diagnostic tools that enhance early detection and enable personalized treatment plans. This has led to improved patient outcomes.
• China: Investment in healthcare infrastructure and research in China has led to the development of advanced biologics and biosimilars for AxSpA. Government initiatives aimed at improving access to medical services have increased demand for these treatments across the population.
• Germany: In Germany, AxSpA treatment is increasingly centered around personalized medicine, with the integration of advanced diagnostic technologies. Collaborative studies between academic institutions and pharmaceutical companies are facilitating the faster development of innovative therapies and improving clinical outcomes.
• India: In India, cost-effective generics and biosimilars dominate the AxSpA market. Recent developments include growing awareness of AxSpA diagnosis and government initiatives aimed at improving healthcare accessibility and affordability.
• Japan: Japan is leveraging its strong pharmaceutical infrastructure to develop next-generation biologics for AxSpA treatment. New therapies have been approved, and the integration of digital health technologies is improving patient care and management.

Features of the Global Axial Spondyloarthritis (AXSPA) Market

Market Size Estimates: Axial spondyloarthritis (axspa) market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Axial spondyloarthritis (axspa) market size by type, drug class, and region in terms of value ($B).

Regional Analysis: Axial spondyloarthritis (axspa) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, drug class, and regions for the axial spondyloarthritis (axspa) market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the axial spondyloarthritis (axspa) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the axial spondyloarthritis (axspa) market to 2030 by technology (thermal, night vision, laser rangefinder, digital storage, and others), stabilization (image stabilized and standard), application (military, astronomy, sports, hunting & shooting, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Axial Spondyloarthritis (AXSPA) Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Axial Spondyloarthritis (AXSPA) Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Axial Spondyloarthritis (AXSPA) Market by Type
  • 3.3.1: Ankylosing Spondylitis (AS)
  • 3.3.2: Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
• 3.4: Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
  • 3.4.1: Non-Steroidal Anti-Inflammatory Drugs (NSAID)
  • 3.4.2: Glucocorticoids
  • 3.4.3: Anti-Rheumatic Drugs
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Axial Spondyloarthritis (AXSPA) Market by Region
• 4.2: North American Axial Spondyloarthritis (AXSPA) Market
  • 4.2.1: North American Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 4.2.2: North American Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
• 4.3: European Axial Spondyloarthritis (AXSPA) Market
  • 4.3.1: European Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 4.3.2: European Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
• 4.4: APAC Axial Spondyloarthritis (AXSPA) Market
  • 4.4.1: APAC Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 4.4.2: APAC Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
• 4.5: ROW Axial Spondyloarthritis (AXSPA) Market
  • 4.5.1: ROW Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 4.5.2: ROW Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Type
  • 6.1.2: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
  • 6.1.3: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Region
• 6.2: Emerging Trends in the Global Axial Spondyloarthritis (AXSPA) Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Axial Spondyloarthritis (AXSPA) Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Axial Spondyloarthritis (AXSPA) Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Janssen Biotech
• 7.2: AbbVie
• 7.3: UCB
• 7.4: Amgen
• 7.5: Novartis Pharmaceuticals Corporation